Global Drug Discovery: Europe Is Ahead
Global Drug Discovery: Europe Is Ahead
复制标题
DOI：
10.1377/hlthaff.28.5.w969
复制
发表时间：
2009-09-01
期刊：
影响因子：
9.7
通讯作者：
Light, Donald W.
中科院分区：
文献类型：
--
作者：
Light, Donald W.
人们普遍认为，美国在制药研究生产力方面已使欧洲黯然失色。一些主要的分析人士声称，尽管在过去的十年里，世界范围内发现的药物越来越少，但大多数都具有重要的治疗作用。然而，1982年至2003年间批准的所有新化学实体的综合数据集表明，美国在研究生产力方面从未超过欧洲，事实上，欧洲的生产力正在领先于美国。其他大型研究表明，大多数新药与先前发现的药物相比，即使有任何临床疗效，也几乎没有。我讨论了国会、雇主和保险公司可以增加药品价值和振兴美国制药业的方法。[卫生事务28，no. 1][5] (2009): w969-w977(2009年8月25日在线发布；10.1377/hlthaff.28.5.w969)]
It is widely believed that the United States has eclipsed Europe in pharmaceutical research productivity. Some leading analysts claim that although fewer drugs have been discovered worldwide over the past decade, most are therapeutically important. Yet a comprehensive data set of all new chemical entities approved between 1982 and 2003 shows that the United States never overtook Europe in research productivity, and that Europe in fact is pulling ahead of U. S. productivity. Other large studies show that most new drugs add few if any clinical benefits over previously discovered drugs. I discuss ways in which Congress, employers, and insurers can increase the value of drugs and revitalize the U. S. pharmaceutical industry. [Health Affairs 28, no. 5 (2009): w969-w977 (published online 25 August 2009; 10.1377/hlthaff.28.5.w969)]